Cloud Hosting

August 31, 2023 8:30 AM | 2 min read

Massive returns are possible within this market! For a limited time, get access to the Benzinga Insider Report, usually $47/month, for just $0.99! Discover extremely undervalued stock picks before they skyrocket! Time is running out! Act fast and secure your future wealth at this unbelievable discount! Claim Your $0.99 Offer NOW!

Advertorial

In this free webinar, learn from subject matter experts (SMEs) on their insights into developing and evaluating rare disease trials in multiple respiratory indications, and learn strategies to overcome obstacles that arise in the clinical development, testing and regulatory approval of treatments for rare diseases.

TORONTO , Aug. 31, 2023 /PRNewswire-PRWeb/ -- Respiratory rare disease trials come with challenges ranging from the demand placed on sites and patients to managing multiple vendors and ensuring diversity. Achieving success in respiratory rare disease trials requires a flexible approach, a strong emphasis on site selection and key opinion leaders (KOLs) with a deep regulatory understanding.

Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!

Achieving success in respiratory rare disease trials requires a flexible approach, a strong emphasis on site selection and key opinion leaders (KOLs) with a deep regulatory understanding.

Join this webinar to hear from subject matter experts (SMEs) on their insights into developing and evaluating rare disease trials in multiple respiratory indications, and learn strategies to overcome obstacles that arise in the clinical development, testing and regulatory approval of treatments for rare diseases.

Join experts from the PPD clinical research business of Thermo Fisher Scientific, Francis Jones, Senior Director Project Management Respiratory; Christian Lloyd, Associate Medical Director; and Terri Myers, Global Head of Biotech Operations, for the live webinar on Monday, September 25, 2023, at 10am EDT ( 4pm CET /EU-Central).

For more information, or to register for this event, visit Respiratory Rare Disease Trials Optimizing Diversity and Decentralization.

Hidden gems are waiting to be found in this market! Don't miss the Benzinga Insider Report, typically $47/month, now ONLY $0.99! Uncover incredibly undervalued stocks before they soar! Limited time offer! Secure your financial success with this unbeatable discount! Grab your 0.99 offer TODAY!

Advertorial

ABOUT XTALKS

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year, thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit http://xtalks.com For information about hosting a webinar visit http://xtalks.com/why-host-a-webinar/

Media Contact

Vera Kovacevic, Xtalks, +1 (416) 977-6555 x371, vkovacevic@xtalks.com

View original content to download multimedia:https://www.prweb.com/releases/respiratory-rare-disease-trials--optimizing-diversity-and-decentralization-upcoming-webinar-hosted-by-xtalks-301914429.html

SOURCE Xtalks

Massive returns are possible within this market! For a limited time, get access to the Benzinga Insider Report, usually $47/month, for just $0.99! Discover extremely undervalued stock picks before they skyrocket! Time is running out! Act fast and secure your future wealth at this unbelievable discount! Claim Your $0.99 Offer NOW!

Advertorial

2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Read this article:

Respiratory Rare Disease Trials -- Optimizing Diversity and Decentralization, Upcoming Webinar Hosted by - Benzinga